Home > Pharmaceuticals >  Mergers and Acquisitions (M&A) in the Pharmaceutical Contract Manufacturing Industry – Implications and Outlook – 2021 Edition

Mergers and Acquisitions (M&A) in the Pharmaceutical Contract Manufacturing Industry – Implications and Outlook – 2021 Edition

Acquisitions of pharmaceutical contract manufacturing organizations (CMOs) are increasing, and the most common type of acquirer is private equity (PE) firms, which view the industry as a prudent choice for a return on investment. This report highlights that between 2018 and 2020, PE firms have shown a rapidly increasing level of investment in the CMO industry. PE firms acquired almost 70 pharmaceutical contract manufacturing companies, and PE-backed CMOs acquired eight during 2018-2020. Private equity firms now own many of the world’s leading CMOs, such as Recipharm, Cambrex Corp, and PCI Pharma Services.

Adam Bradbury, PharmSource Analyst at GlobalData, comments: “The Tax Cuts and Jobs Act of 2017, passed under President Trump, reduced corporation tax rates and made it more profitable to be a private equity firm. This has, in effect, increased the spending power of these companies and contributed to the rising levels of investment in the CMO industry.”

GlobalData’s report states that PE-backed CMOs will find they have a lot more financial support to add to their service offerings and value. All the top CMOs recently acquired by private equity firms were in turn active acquirers of other CMOs or contract manufacturing facilities.

Bradbury continues: “The COVID-19 pandemic has brought mixed fortunes for the CMO industry. Although M&A activity was higher over the 2018-2020 period than previously, it declined somewhat between 2019 and 2020. Nonetheless, private equity presence in the CMO industry is growing and investor appetite is strong.”

Supply chain disruption and problems with mass vaccine production mean there are currently significant opportunities for CMOs, and they represent a prudent investment opportunity, with vaccine developers in particular signing contract service agreements at an unprecedented rate.

Bradbury concludes: “Even during the height of the COVID-19 crisis in 2020, large CMOs such as Fareva, Delpharm, Catalent, Vetter, and Piramal Pharma Solutions were acquiring companies, showing that large CMOs mergers and acquisitions (M&A) activity is not deterred by the uncertainty of the COVID-19 predicament.”


This report is the third edition of our analysis of mergers and acquisitions in the pharmaceutical contract manufacturing industry. PharmSource is the most definitive, trustworthy source of strategic insight on this topic in the bio/pharmaceutical realm. It provides:

  • Overview of M&A in the Pharma CMO Industry
  • Detailed view of CDMO performance by number of deals completed from GlobalData’s Deals database
  • Analysis of the M&A of specific manufacturing services


Reasons to Buy

Who should buy this report?

This 55-page report gives important, expert insight you won’t find in any other source. 28 tables and figures throughout the report illustrate major points and trends. This report is required reading for:

• CMOs: market trends, strategic planning, competitive intelligence, performance benchmarking

• Bio/Pharma: supplier performance benchmarking, market trends, competitive intelligence

• Private equity and Stock analysts: target identification and analysis, portfolio company performance benchmarking

Companies Mentioned

3P Biopharmaceuticals SL

A. Menarini Industrie Farmaceutiche Riunite Srl

AB BioTechnologies Inc


ABS (Aus) Pty Ltd

Absorption Systems LLC

Abzena Ltd

Ache Laboratorios Farmaceuticos SA

ACS Dobfar SpA

ADC Biotechnology Ltd

Advent International Corp

AGC Biologics Inc


Akron Biotechnology LLC

Alcaliber SA

Alcami Corp

Aldevron LLC

Alliance Contract Pharma LLC


Altasciences Co Inc

AmbioPharm Inc

AMPAC Fine Chemicals LLC

Ampersand Capital Partners

Anjan Drug Pvt Ltd

Aphena Pharma Solutions Inc

AptarGroup Inc

Arc Trinova Ltd

Arcline Investment Management LP

Ardena Holding NV

Arena Pharmaceuticals GmbH

As Produksjonslab AS

Asahi Kasei Pharma Denmark A/S

Ascendis Health Ltd

AstraZeneca Plc

Astro Bidco Ltd

Aurisco Pharmaceutical Co Ltd

Avaca Pharma

Avanti Polar Lipids Inc

Avara Pharmaceutical Services Inc

Avista Capital Holdings LP

Bain Capital Private Equity LP

Bayer AG

Benchmark Holdings PLC

Berkshire Sterile Manufacturing Inc

BGF Investments LP

Bio V Pharma Inc

BioAgilytix Labs LLC

Bio-Concept Laboratories Inc

Biocult BV

BioDuro LLC

Biogen Denmark Manufacturing ApS

Bionova Scientific Inc

BioScreen Testing Services Inc

Biospring Partners

BioVectra Inc

Biovian Oy

Bora Pharmaceuticals Co Ltd

Bridgepoint Advisers, Ltd.

Bridgewest Australia Holdings LLC

BrightGene Bio-Medical Technology Co Ltd

Bristol-Myers Squibb Co

C.O.C. Farmaceutici Srl

Cadila Healthcare Ltd

Cambrex Corp

Capua BioServices SpA

Carlyle Asia Partners V LP

Catalent Inc

Cell and Gene Therapy Catapult


Cellix Bio Pvt Ltd

Centrient Pharmaceuticals Netherlands BV

Charles River Laboratories International Inc

Charnwood Molecular Ltd

ChemConnection BV

Chemical Solutions Ltd

CiToxLAB Group

Civentichem LLC

Claris Lifesciences Ltd

Clean Cells SAS

Clinigen Group Plc

Cobepa SA

Cobra Biologics Ltd

Cognate BioServices Inc

Concept Life Sciences Ltd

Consort Medical Ltd

Contract Pharmaceutical Services of Australia Pty Ltd

Control Laboratory & Analysis SA


Corona Remedies Pvt Ltd

Cosette Pharmaceuticals Inc

Covance Inc

Croda International Plc

C-squared Pharma Sarl

Curida AS

CX Partners LLP


Dalton Pharma Services

Danaher Corp

Delpharm SAS

Dhanuka Laboratories Ltd

Dr. Reddy’s Laboratories Ltd

Echo Pharmaceuticals BV

Elion Labs


Escientia Life Science LLC

Eubioco SA

Eurofins Advinus Ltd

Eurofins Scientific SE

Euticals SpA

Evotec SE

EW Healthcare Partners

Famar Health Care Services

Fareva SA

Farmaceutici Procemsa SpA

Flamma SpA

FPCI Capital Sante 2

Frontage Laboratories Inc

FTF Pharma Pvt Ltd

Fujifilm Diosynth Biotechnologies USA Inc

Fujifilm Holdings Corp

FUJIFILM Toyama Chemical Co Ltd

G&W Laboratories Inc

Gamot API Pte Ltd

General Atlantic LLC

Genovis AB

Genscript Biotech Corp

GHO Capital Partners LLP

GlaxoSmithKline Plc

Gomti Life Sciences India Private Limited

Goodwin Biotechnology Inc

Granules-Biocause Pharmaceutical Co Ltd

Great Point Partners, LLC

H.I.G. Capital LLC

Hebei Hejia Pharmaceutical Group Co Ltd

Hikma Pharmaceuticals Plc

Honeywood Ltd

Horizon Discovery Group Plc

Hubei Biocause Pharmaceutical Co Ltd

Hycult Biotech BV

Impopharma Canada Ltd

Importfab Inc

India Life Sciences Fund II

India Life Sciences Fund III

Industria Chimica Emiliana SpA

Industria Farmaceutica Melcon do Brasil SA

Infinity Laboratories

Intas Pharmaceuticals Ltd

Intermediate Capital Group Plc

Investindustrial Growth

IPCA Laboratories Ltd

Iwaki & Co Ltd

Iwaki Seiyaku Co Ltd

Jiangsu Chengxin Pharmaceutical Co Ltd

Jiangxi Fushine Pharmaceutical Co Ltd

JSC Biocom

JSFC Sistema

Juniper Pharmaceuticals Inc

Just Evotec Biologics Inc

Kalexsyn Inc

KBI Biopharma Inc

Keensight Capital

Kemp Proteins LLC

Kirin Holdings Co Ltd

Kohlberg & Company LLC

Konsyl Pharmaceuticals Inc

Kymos Pharma Services SL

Kyowa CritiCare Co Ltd

Kyowa Hakko Bio Co Ltd

La Chandra Pharmalab Pvt Ltd

Laboratorium fur Betriebshygiene GmbH


Leonard Green & Partners LP

LGM Pharma LLC

LIVIA Corporate Development SE

Lonza Group Ltd

Lusomedicamenta – Sociedade Tecnica Farmaceutica, S.A

Lyophilization Services of New England Inc

Madison Dearborn Partners LLC

Malgrat Pharma Chemicals, S.L.U.

MaSTherCell SA

Mercachem-Syncom Group

Mercia Asset Management PLC

Merck & Co Inc

Mikart Inc

Minaris Regenerative Medicine GmbH FKA apceth Biopharma GmbH

Minaris Regenerative Medicine LLC

Mitsubishi Chemical Holdings Corp

Mitsubishi Tanabe Pharma Corp

MolMed SpA

MPI Research Inc

Murli Krishna Pharma Pvt Ltd

Naari Pharma Pvt Ltd

Nanjing Hongjing Enterprise Management Consulting Co., Ltd.


Natural Capsules Ltd

Nautic Partners, LLC

neo ALA Co Ltd

Nevu Sp Zoo

New England Peptide Inc

New Zealand Pharmaceuticals Ltd

Nexgen Pharma Inc

Nipro Pharma Corp

Nitin Lifesciences Ltd

Novartis AG

Novast Holdings Ltd

Nx Phase Capital Inc.

Olon Ricerca Biosciences LLC

Olon SpA

Opocrin SpA

Orchid Pharma Ltd

Orifarm Group A/S

Oxford Genetics Ltd

Pace Analytical Services LLC

PAMA Holding Sarl

Paragon Bioservices Inc

Patheon NV

Patheon Viral Vector Services

PCI Pharma Services

Peptides International Inc

Permira Advisers LLP

Pfizer Inc

PharmaBlock Sciences Nanjing Inc

Pharmaceutical Associates Inc

Pharmaceutical Packaging Professionals Pty Ltd

Pharmaron Beijing Co Ltd

Pharmatis SAS

PharmaZell GmbH

Pihex – Investimentos Imobiliarios, Lda

Pilatus Pharma Ltd

Piramal Pharma Solutions Inc

Pisgah Labs Inc

Porton Pharma Solutions Ltd

Probiotec Ltd

Prolytic GmbH

Pronomz Ventures LLP

PSC Biotech Corp

QED Bioscience Inc

Quadrants Scientific Inc

Quality Packaging Specialists International LLC

Quotient Sciences Ltd

RA Chem Pharma Ltd

Raichem Medicare Pvt Ltd

Ramdev Chemicals Pvt Ltd

Recipharm AB

Rentschler Biopharma SE

Rubicon Research Pvt Ltd

Samco Gold Limited

Sandoz Industrial Products SpA


Seikagaku Corp

Selcia Ltd


Shandong Jincheng Pharmaceutical and Chemical Co Ltd

Shandong Luoxin Pharmaceutical Group Stock Co Ltd

Shanghai Ruiyi Investment Development Center

Sharp Packaging Services

Shilpa Medicare Ltd

Shire Pharmaceuticals International UC

SI Group Inc

Siegfried Holding AG

Signet Healthcare Partners

SIX.02 Bioservices LLC

SK Capital Partners LP

SK Inc

Solara Active Pharma Sciences Ltd

Solvias AG

SONEAS Chemicals Ltd

Sorrento Therapeutics Inc

Spectris Plc

Spera Pharma Inc

STA Pharmaceutical Co Ltd

Stemline Therapeutics Inc

Sterling Pharma Solutions Ltd

Strides Chemicals Private Limited

Strides Pharma Science Ltd


SuanFarma SA

Symbiotec Pharmalab Ltd

SYNLAB Analytics & Services Germany GmbH

Synova Capital LLP

Syntagon AB

Tanabe Seiyaku Yoshiki Factory Co., Ltd.

Tergus Pharma LLC

Teva Pharmaceutical Industries Ltd

Teva Takeda Pharma Ltd

The Carlyle Group LP

The EQT VIII fund

Therapiva Pvt Ltd

Tjoapack BV

Torii Pharmaceutical Co Ltd

TPG Growth LLC

TriPharm Services Inc

Tubilux Pharma SpA

UI Gestion SA

ValueAct Capital Management, L.P.

Veeda Clinical Research Pvt Ltd

VelaLabs GmbH

Velesco Pharmaceutical Services LLC

Veloxis Pharmaceuticals AS

Vetter Pharma-Fertigung GmbH & Co KG

Viatris Inc

Vibalogics GmbH

Vigene Biosciences Inc

Viva Biotech Shanghai Ltd

Vivimed Labs Spain SL

Vivimed Life Sciences Pvt Ltd

Wasdell Packaging Group

Weifang Yaxing Chemical Co Ltd

Windlas Biotech Pvt Ltd

Windlas Healthcare Pvt Ltd

WuXi AppTec Co Ltd

WuXi Biologics Cayman Inc

WuXi Pharmatech (Cayman) Inc

Xiamen Kingdomway Group Co

Zhejiang Better Pharmaceuticals Co Ltd

Zhejiang Doyin Pump Industry Co., Ltd.

Zhejiang Hisyn Pharmaceutical Co Ltd

Zhejiang Jiuzhou Pharmaceutical Co Ltd

Zhejiang Langhua Pharmaceutical Co Ltd

Zhejiang Raybow Pharmaceutical Co Ltd

Zhejiang Starry Pharmaceutical Co Ltd

Zhejiang Sunflower Light Energy Science & Technology LLC

Table of Contents

About GlobalData

Executive Summary



Industry Analysis

Objectives and Methodology

Overview of M&A Activity 2018–2020

Target Characteristics

Acquirer Characteristics


Top Acquirers

Segment Close-Ups of M&A Activity, 2018–2020


API—Small Molecule

Commercial Dose Manufacturing

Analytical Services


Deal Advisors

Top Financial Advisors

Top Legal Advisors


Facility Acquisitions

What It Means

The Outlook for M&A

API—Biologic Targets

Past Predictions

Value Chain





Primary Research – Key Opinion Leaders

Further Reading

About the Authors

Contact Us

List of Tables

Table 1: CMO M&A Trends, 2018–2020

Table 2: Company Acquisitions by Target Service Offering and Year, 2018–2020

Table 3: Company Acquisitions by Target Service Offering and Target Ownership, 2018–2020

Table 4: Company Acquisitions by Target Service Offering and Deal Region, 2018–2020

Table 5: Company Acquisitions by Target Service Offering and Acquirer Ownership, 2018–2020

Table 6: Services Deals with Known Transaction Value and Multiples, 2018–2020

Table 7: Facility Acquisitions by CMOs, 2018–2020

Table 8: Acquisitions by PE Firms, 2018–2020

Table 9: Potential Targets: API—Biologic (Protein & Peptide) Service Providers

Table 10: Potential Targets: API—Biologic (Gene and Cell Therapy) Service Providers

Table 11: Company Acquisitions and Private Equity Deals, 2018–2020

Table 12: Further Reading

List of Figures

Figure 1: Leading Acquirers in the Global Pharma CMO Industry, 2018–2020

Figure 2: Top M&A Trends in the CMO Industry, 2018–2020

Figure 3: CMO M&A Activity, 2018–2020

Figure 4: CMO M&A Activity by Year, 2018–2020

Figure 5: Company Acquisitions by Target Service Offering, 2018–2020

Figure 6: Company Acquisitions by Target Ownership, 2018–2020

Figure 7: Acquisition Targets by Sophistication of Capabilities

Figure 8: Number of Acquisitions 2018–2020 by Acquirer’s Core Business

Figure 9: Number of Acquisitions by Acquirer’s Ownership

Figure 10: Number of Acquisitions by Deal Country (Top Four), 2018–2020

Figure 11: Most Active Acquirers, 2018–2020

Figure 12: Dose Forms Manufactured by Acquired Dose Manufacturers, 2018–2020

Figure 13: Top Financial Advisors to Company Acquisitions, 2018–2020

Figure 14: Company Acquisition Top Legal Advisors, 2018–2020

Figure 15: Pharma CMO Facility Acquisitions, 2018–2020

Figure 16: The Contract Manufacturing Value Chain


Discounts available for multiple purchases.

+44 20 7947 2960

Join our mailing list

Saved reports